We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Vizient Links FDA’s Unapproved Drugs Initiative to Higher Drug Costs
Vizient Links FDA’s Unapproved Drugs Initiative to Higher Drug Costs
Drugs approved through the FDA’s Unapproved Drug Initiative could potentially cost $29 billion in extra healthcare costs, Vizient said in a new analysis released this week.